Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

90 References Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196(4286):129–36. Castrejo ...

91 Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, et al. Disparities in rheumatoid arthr ...

92 Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med. 1996;156(13): ...

93 Pincus T, Maclean R, Yazici Y, Harrington JT. Quantitative measurement of patient status in the regular care of patients wit ...

94 Bergman MJ, Castrejon I, Pincus T. RHEUMDOC: a one-page rheumatology doctor form with four physician global estimates for ov ...

95 Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire m ...

96 Park SH, Choe JY, Kim SK, Lee H, Castrejon I, Pincus T. Routine assessment of patient index data (RAPID3) and bath ankylosin ...

97 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modifi ed disease activity scores that incl ...

98 Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defi ning functional ability in a ...

99 Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treat ...

© Springer International Publishing Switzerland 2016 101 Y. El Miedany (ed.), Patient Reported Outcome Measures in Rheumatic Dis ...

102 is not part of the ACR core set of RA outcomes, outcome measures in rheumatology (OMERACT), in 2006, endorsed the inclusion ...

103 Gradually, patient-reported outcomes in RA gained momentum as research studies documented its value in standard clinical pra ...

104 Prognostic Marker The introduction of the early arthritis concept and the “window of opportunity” widened the scope to inclu ...

105 patients’ consecutive PROMs scores recorded with them. Electronic recording of the data obtained facilitated expressing thes ...

106 Cost-Effectiveness Cost-effectiveness is not a straightforward concept as it encompasses elements not directly measurable in ...

107 when RA treatment causes or contributes to comorbidity development; e.g., steroids and infection. Finally, type-VI comorbidi ...

108 fering from infl ammatory arthritic conditions, a mutual index of several measures has been recommended for assessment of di ...

109 outcomes and results of care. An earlier report [ 70 ] highlighted that pain, function, and RAPID scores should be considere ...

110 Application of the Concept of Personalized Medicine in Rheumatoid Arthritis The healthcare services worldwide are now both l ...